Vendor Intelligence Report: Qingdao Hongshengda Trading

Published 13 Jun 2026. 22-page investigative report on who is behind Qingdao Hongshengda Trading: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Qingdao Hongshengda Trading has a small but consequential Finnrick record: 4 Finnrick lab tests, 3 pass / 1 fail — overall pass rate 75%. Every recorded test is Tirzepatide, so the vendor has shown it can sometimes ship the labeled compound, but the same record includes a complete Tirzepatide identity failure. With only four tests, ratings move sharply under stricter grading and the record cannot be generalized across the 36-product catalog.

The public identity trail is thinner than the sales pitch. The site claims operations dating to 2019 and broad international reach, while the corroborated web footprint begins in 2025; Chinese registry searches, ICP checks, and import-record searches did not produce a verifiable Qingdao Hongshengda Trading entity. A linked Facebook page adds a generic China Peptide Supplier identity and a U.S. address the investigation treats as fabricated.

The buyer read is therefore product-specific: Tirzepatide is not a pure non-identity operation in Finnrick data, but the identity failure and batch-label inconsistency keep it out of the reasonable-choice tier. Everything else on the site — including Semaglutide, Retatrutide, BPC157, and HGH — has no Finnrick product record and no public COA infrastructure. Ordering is inquiry-based, with no visible pricing, checkout, refund terms, or regulated payment recourse.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with per-product pass/fail detail and methodology-divergence charts for the tested product
  • Certificate-level analysis of the Tirzepatide identity failure and same-batch consistency problem
  • Claim-versus-record timeline covering the 2019 history claim, 2025 domain evidence, SSL record, and archive trail
  • Corporate and infrastructure review across Chinese registries, WHOIS, ICP status, hosting, and xuansiwei platform identifiers
  • Catalog and sales-model analysis of the 36 public product listings, COA gaps, pricing absence, and regulated-product exposure
  • Reputation and promotion sweep covering Facebook, Reddit/forum visibility, coupon pages, X referral signals, and documented dead ends

Risk assessment

  • Tirzepatide identity and batch-consistency risk — high: One Finnrick Tirzepatide sample, batch 07152025 / test 20251017-e-xmfyzgr, contained no Tirzepatide; another sample with the same batch ID later passed, making batch labels unreliable.
  • Unverifiable corporate identity and location claims — high: No Chinese registry record, ICP record, or named personnel were found for Qingdao Hongshengda Trading Co., Ltd; the linked Facebook page lists an invalid U.S. address.
  • Misleading operating-history and reach claims — high: The site claims 2019 operations and 50-country coverage, while the corroborated web trail begins in 2025 and no U.S. import record was found.
  • Catalog documentation gap — high: No public COAs, signed batch records, verification portal, or third-party test reports were found for the 36-product catalog, including Tirzepatide.
  • Controlled-substance and regulatory exposure — high: The catalog lists HGH, MT-2, and HCG without jurisdiction-specific regulatory or prescription-compliance documentation.
  • Opaque sales and payment-recourse risk — medium: No prices, cart, checkout, payment gateway, refund terms, or visible recourse channel were observed; orders route through email and WhatsApp.
  • Market-reputation gap — medium: No community reviews, Reddit/forum discussions, coupon pages, or X promoter mentions were found; the direct Reddit JSON sweep failed and several social platforms were not swept.